295 Results
Sort By:
Published on June 15, 2017
Human Longevity Inc. (HLI) said today it has joined with Merck KGaA to identify treatment response biomarker signatures in patients with advanced melanoma, through a joint pilot project whose value was not disclosed. HLI and Merck KGaA will focus on identifying biomarkers in patients with locally advanced or metastatic NRAS…
Published on June 5, 2017
The more diverse the digestive tract bacteria, the slower the progression of metastatic melanoma in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center reported today. At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the researchers presented results from a…
Published on April 28, 2017
The Melanoma Research Alliance (MRA) said today it has awarded more than $8.5 million in new funding, in 34 new research awards, to 28 institutions in six countries, all aimed at advancing treatment and understanding of the most serious type of skin cancer. The grants are intended to fund programs…
Published on September 7, 2016
Researchers from the Swiss Nanoscience Institute, the University of Basel, and the University Hospital Basel have developed a new nanotechnology based method to rapidly detect genetic mutations in patients with malignant melanoma. Findings from the new study, “Fast Diagnostics of BRAF Mutations in Biopsies from Malignant Melanoma”, were published recently…
Published on June 21, 2016
Cancer Moonshot 2020, a comprehensive cancer collaboration of pharmaceutical and biotech companies, academic cancer centers, community oncologists, and communications technology companies, has announced the formation of the melanoma and sarcoma working group with the goal of speeding promising immunotherapies to clinical trials. The working group will be chaired by Richard…
Published on March 1, 2016
Researchers at the University of Miami Miller School of Medicine discovered a biomarker that puts patients at a higher risk for metastasis of uveal melanoma, a type of eye cancer. Among uveal melanomas categorized as class 1, those with high levels of the biomarker PRAME mRNA were more likely to…
Published on April 5, 2024
Obsidian Therapeutics this week closed an oversubscribed $160.5 million Series C financing to try and crack the immunotherapy for solid tumors problem. The financing was led by Wellington Management. Obsidian’s lead candidate, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) “armored with pharmacologically…
Published on April 3, 2024
By analyzing the nearly 6,000 Major Histocompatibility Complex-1(MHC-1) proteins in the human body, researchers from Arizona State University (ASU) were able to classify them into 11 different types according to their electrostatic signatures. Their new human leukocyte antigen (HLA)-Inception tool, created by AI and machine learning, revealed that individuals with…
Published on February 28, 2024
New research shows that targeting the activin receptor 1C on T cells may boost immune system attack against cancer cells. As a potential new anticancer immunotherapy, it opens the door to new treatment protocols aimed at blocking its function. The team first found that the levels of protein activins, including…
Published on February 21, 2024
Researchers from the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health, and the Bloomberg-Kimmel Institute for Cancer Immunotherapy have released new findings that show fibroblasts are altered by aging and this helps promote tumor growth, which may explain why pancreatic cancer is more aggressive in…
Published on February 14, 2024
Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the National Institutes of Health, and The University of Texas MD Anderson Cancer Center, have shed light on the intricate immune responses within cancerous tumors. By analyzing data from over 1,000 tumors spanning 10 different types of…
Published on January 30, 2024
New research from investigators at the Cancer Research UK Scotland Institute and Memorial Sloan Kettering Cancer Center has shown that immunotherapy is two-and-a-half times more effective in tumors that have mitochondrial DNA (mtDNA) mutations. The researchers made the discovery after creating mutations in parts of the mtDNA, a finding that…
Published on January 24, 2024
A new report in Trends in Cancer analyzes the prospects of tissue-agnostic therapeutics in patients with primary brain tumors (PBTs). The paper was written by researchers from Miami Cancer Institute, part of Baptist Health South Florida. In it, the researchers discuss data from clinical trials of tissue-agnostic targets for PBTs…
Published on January 17, 2024
Individuals with obesity are more likely to have a benign blood condition that often precedes multiple myeloma, according to new research to be published in Blood Advances. People who are physically active, meanwhile, are less likely to have this condition, even if they are obese. Smoking and too little sleep…
Published on January 4, 2024
A rare type of T immune cell can help predict which patients may benefit most from cancer immunotherapies, a new study has found. The study was published in Nature Cancer and led by researchers from King’s College London, Guy’s and St Thomas’ Hospital Trust, and the Francis Crick Institute. “Checkpoint inhibition (CPI),…